Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC).

446Background: Several PD-1 immune-checkpoint inhibitors including Nivolumab (Nivo) are approved in urothelial cancer. Recently, in the front line setting, improved activity of combined PD-L1 and C...